Current Medicinal Chemistry

Editor-in-Chief

Atta-ur-Rahman, FRS
(32052 citations)
Kings College
University of Cambridge
Cambridge
(UK)

Nobel Laureates on Editorial Board

Prof. John Gurdon
(UK)

Prof. Jean-Marie Lehn
(France)

Prof. Ferid Murad
(USA)

Personal Subscription
Become EABM
Become Reviewer
Call for Editor
Volume: 19 Issue: 7, March

Editorial [ Hot Topic: Targeting Tumor Angiogenesis: An Update (Guest Editor: Girolamo Ranieri)]

Volume:19   Issue: 7
Pp: 937-937
Girolamo Ranieri
DOI: 10.2174/092986712799320718
Published on: 01 March, 2012

Sorafenib (BAY 43-9006) in Hepatocellular Carcinoma Patients: From Discovery to Clinical Development open access plus

Volume:19   Issue: 7
Pp: 938-944
G. Ranieri, G. Gadaleta-Caldarola, V. Goffredo, R. Patruno, A. Mangia, A. Rizzo, R. L. Sciorsci and C. D. Gadaleta
DOI: 10.2174/092986712799320736
Published on: 01 March, 2012

mTOR as a Target of Everolimus in Refractory/Relapsed Hodgkin Lymphoma

Volume:19   Issue: 7
Pp: 945-954
A. Guarini, C. Minoia, M. Giannoccaro, A. Rana, A. Iacobazzi, A. Lapietra, A. Raimondi, N. Silvestris, C. D. Gadaleta and G. Ranieri
DOI: 10.2174/092986712799320727
Published on: 01 March, 2012

Inflammation and Antiangiogenesis in Cancer

Volume:19   Issue: 7
Pp: 955-960
D. Ribatti, E. Crivellato and A. Vacca
DOI: 10.2174/092986712799320655
Published on: 01 March, 2012

Bevacizumab in Non Small Cell Lung Cancer: Development, Current Status and Issues

Volume:19   Issue: 7
Pp: 961-971
C. Sandomenico, R. Costanzo, G. Carillio, M. C. Piccirillo, A. Montanino, M. Di Maio, G. Rocco, N. Normanno, F. Perrone and A. Morabito
DOI: 10.2174/092986712799320673
Published on: 01 March, 2012

Efficacy and Safety of Bevacizumab in Glioblastomas

Volume:19   Issue: 7
Pp: 972-981
S. De Fazio, E. Russo, M. Ammendola, E. Donato Di Paola and G. De Sarro
DOI: 10.2174/092986712799320646
Published on: 01 March, 2012

The Pharmacological Pathways of GnRH Mediating the Inhibition of Mammary Tumours: Implications in Humans and Domestic Animals

Volume:19   Issue: 7
Pp: 982-991
A. Rizzo, M. Spedicato, M. Mutinati, G. Minoia, R. Patruno, G. Ranieri and R. L. Sciorsci
DOI: 10.2174/092986712799320745
Published on: 01 March, 2012

DC-SIGN Antagonists, a Potential New Class of Anti-Infectives

Volume:19   Issue: 7
Pp: 992-1007
M. Anderluh, G. Jug, U. Svajger and N. Obermajer
DOI: 10.2174/092986712799320664
Published on: 01 March, 2012

Disease-Modifying Therapies in Frontotemporal Lobar Degeneration

Volume:19   Issue: 7
Pp: 1008-1020
B. Bigni, E. Premi, A. Pilotto, A. Padovani and B. Borroni
DOI: 10.2174/092986712799320637
Published on: 01 March, 2012

The Development of MetAP-2 Inhibitors in Cancer Treatment

Volume:19   Issue: 7
Pp: 1021-1035
S.-Q. Yin, J.-J. Wang, C.-M. Zhang and Z.-P. Liu
DOI: 10.2174/092986712799320709
Published on: 01 March, 2012

MMP-2 Selectivity in Hydroxamate-Type Inhibitors

Volume:19   Issue: 7
Pp: 1036-1064
P. Serra, M. Bruczko, J. M. Zapico, A. Puckowska, M. A. Garcia, S. Martin-Santamaria, A. Ramos and B. de Pascual-Teresa
DOI: 10.2174/092986712799320628
Published on: 01 March, 2012

Pharmacological Strategies to Overcome HER2 Cross-Talk and Trastuzumab Resistance open access plus

Volume:19   Issue: 7
Pp: 1065-1075
R. Nahta
DOI: 10.2174/092986712799320691
Published on: 01 March, 2012

Gemcitabine: A Critical Nucleoside for Cancer Therapy

Volume:19   Issue: 7
Pp: 1076-1087
D. S. Gesto, N. M.F.S.A. Cerqueira, P. A. Fernandes and M. J. Ramos
DOI: 10.2174/092986712799320682
Published on: 01 March, 2012